RxDoctor Payments Data

Kurtis Munzer, DO

Pulmonary Disease · Saint Louis, MONPI 1396087540

Payments from drug & device makers

$7,272in general payments, 2019–2025

Across 72 payments — averaging $101.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Intuitive Surgical$992
  • Veran Medical Technologies, Inc.$836
  • GSK$255
  • Actelion Pharmaceuticals US, Inc.$230
  • Sanofi$204
  • plus $748 from 14 others

What the payments were for

  • Speaking & faculty fees$3,75052%
  • Travel & lodging$1,43720%
  • Food & beverage$2,08529%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,272 in reported general payments places this provider in the 65th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$92,078
Medicare patients
393
Services billed
1,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter359$293,608
OfevNintedanib Esylate18$234,914
Breztri AerosphereBudesonide/Glycopyr/Formoterol157$115,732
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr157$84,964
Stiolto RespimatTiotropium Br/Olodaterol Hcl90$56,636
Dupixent PenDupilumab14$53,279
Breo ElliptaFluticasone/Vilanterol80$33,304
SymbicortBudesonide/Formoterol Fumarate80$23,333
EliquisApixaban38$20,412
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate71$17,649
Tadalafil14$14,476
Spiriva RespimatTiotropium Bromide17$12,624
Spiriva HandihalerTiotropium Bromide15$11,420
ArexvyRsvpref3 Antigen/As01e/Pf35$9,708
Albuterol Sulfate HfaAlbuterol Sulfate390$8,792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy, Incruse Ellipta$255$436,284675 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$119$309,485136 claims
AstraZenecaBreztri Aerosphere, Symbicort$4,006$139,065237 claims
PfizerEliquis, Abrysvo$15$27,16760 claims
MerckDulera$14$6,53219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →